CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04276207
NCT04276207Phase 1Completed
CompareCT.gov

Effects of LY900014 on Recovery From Hyperglycemia Compared to Humalog in Subjects With Type 1 Diabetes Mellitus (T1DM) on Continuous Subcutaneous Insulin Infusion

Eli Lilly and Company·interventional·Posted Feb 19, 2020·Updated Aug 25, 2021

In Brief

A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro for Diabetes Mellitus, Type 1. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The main purpose of this study is to compare LY900014 to insulin lispro (Humalog) in participants with type 1 diabetes who are using an insulin pump and have high blood sugar after eating. For each participant, the study will last about two to nine weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedFeb 19, 2020
Enrollment StartFeb 25, 2020
Primary CompletionAug 10, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.4 years ago

Interventions

LY900014drug

Administered by CSII

Insulin Lisprodrug

Administered by CSII